PDE6A Gene Therapy for Retinitis Pigmentosa

STATUS

Recruiting
End date

Dec 26, 2025
participants needed

9
sponsor

STZ eyetrial

Updated on 26 January 2021

See if I qualify

gene therapy

other disease

Summary

The PDE6A gene encodes a subunit of the rod phosphodiesterase. The loss of this enzyme function leads to a chronically elevated cGMP level which causes an increased calcium inflow into the cell and thereby the hyperactivation of cell death pathways. The goal of the PIGMENT study is to develop, produce and investigate a recombinant adeno-associated viral (AAV) gene transfer vector for the curative therapy of PDE6A-linked retinitis pigmentosa in patients, in order to counteract their disease progression and to stop further impairment of visual function. The vector is given with a single subretinal injection.

Description

"PIGMENT - Subretinal PDE6A gene therapy for retinitis pigmentosa" is an open mono-center, phase I/IIa trial with fellow-eye comparison.

The study begins with a detailed preliminary examination (Screening), comprises a total of 13 visits and ends after one year. In between, after the gene therapy injection (injection of the vector under the retina with one of four doses), regular controls are carried out at the Center for Ophthalmology Tbingen. Monitoring will be contimued after the first year, once a year two, three, four and five years after the injection. The study will take place exclusively at the Center for Ophthalmology in Tbingen and involves nine patients.

All patients participating in this study receive treatment, i.e. there is no placebo or sham treatment group. A 30-day safety distance is maintained between each patient and each group. An independent committee will decide, after each injection of three patients, which dose the following three patients will receive.

Patients can benefit from the treatment by slowing or stopping the loss of the rods and allowing them to function to a certain extent. Therefore, a possible benefit for patients may be that the vision problems will be improved by gene therapy. Such improvements could improve the overall quality of life and well-being. However, as no experience with gene therapy for retinitis pigmentosa in humans has yet been gained, we cannot promise any improvement. Within the scope of this study, patients will be given particularly intensive care and psychological support will also be offered in order to do everything for the patient's well-being and health during the study.

Time Schedule: Start of trial Q3/2019 (FPFV), end of recruitment Q3/2020, end of trial Q4/2025 (LPLV), duration of trial per patient: one year with four years of follow-up. The final study report will be prepared after completion of the four year follow-up period (5 years after treatment).

Details

Condition	Retinitis Pigmentosa, Retinitis Pigmentosa
Treatment	subretinal injection of rAAV.hPDE6A
Clinical Study Identifier	NCT04611503
Sponsor	STZ eyetrial
Last Modified on	26 January 2021

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	clinical diagnosis of retinitis pigmentosa
	confirmed mutation in PDE6A gene
	years of age
	visual acuity 20/400
	no infection with Human Immundeficiency Virus (HIV)
	negative pregnancy test in women with childbearing potential (a woman who is two years post-menopausal or surgically sterile is not considered to be of childbearing potential)
	Male patients must agree to use condoms during the first 6 months post treatment
	Female patients of childbearing potential must agree to use an effective method of birth control during the first 6 months post treatment
	ability to understand and willingness to consent to study protocol
Exclusion Criteria
	Ocular (study eye & fellow eye)
	additional interfering ocular conditions with impact on study results (e.g. ocular opacity and advanced cataract, uveitis, amblyopia)
	recent (6 months) ocular surgery, intravitreal or subretinal implantation of a medical device
	disease causing mutations in another known retinitis pigmentosa gene
	ocular infection with herpes simplex virus in medical history
	history of ocular malignancies
	disorders of the internal retina (e.g. retinal detachment in the patients history)
	glaucoma defined as damage of the optic nerve
	vascular retinal occlusion
	diabetic patients suffering from retinopathy and/or macula edema
	any other retinopathy due to other diseases e.g. (but not limited to) arterial hypertension, trauma or acquired inflammatory diseases (uveitis serology), contraindication to pharmacological mydriasis (e.g. history of angle block glaucoma)
	absence of visual function on the contralateral eye Systemic
	systemic conditions (e.g. coronary heart disease, autoimmune disorders) which may affect study participation or outcome measures
	History of poorly controlled Diabetes Mellitus type 1 or type 2
	systemic illness or medically relevant abnormal laboratory values in blood analysis including renal and hepatic functions at inclusion
	patients treated with oral corticoids within 14 days prior inclusion
	current or recent participation in other study/or administration of biologic agent within the last three months
	known sensitivity to any compound used in the study
	contraindications to systemic immunosuppression
	contraindications in view of the planned surgery (e.g. but not limited to anaemia Hb<10g/dl, coagulopathy with PT/PTT >1,5 fold upper limit, hypertension with values above 180 mmHg systolic and 110 mmHg diastolic) including intolerance and contraindications to general anaesthesia
	intolerance to contrast agents used for diagnostic methods like angiography with fluoresceine or indocyanine green (e.g. but not limited to hyperthyroidism, hepatic insufficiency)
	subject/partner of childbearing potential unwilling to use adequate contraception for four months
	nursing or pregnant women
	any other cause that, in the investigator's opinion, renders potential subjects not suitable for the study

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

gene therapy

other disease

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Edit Delete

Added by •

•

Private

Edit Delete

Reply by • • Private

Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

Enter the passcode

The passcode will expire in None.

PDE6A Gene Therapy for Retinitis Pigmentosa